CY1110841T1 - Σταθεροποιημενος φαρμακευτικος παραγοντας λευκοτριενιου β4 (ltb4) - Google Patents

Σταθεροποιημενος φαρμακευτικος παραγοντας λευκοτριενιου β4 (ltb4)

Info

Publication number
CY1110841T1
CY1110841T1 CY20101100940T CY101100940T CY1110841T1 CY 1110841 T1 CY1110841 T1 CY 1110841T1 CY 20101100940 T CY20101100940 T CY 20101100940T CY 101100940 T CY101100940 T CY 101100940T CY 1110841 T1 CY1110841 T1 CY 1110841T1
Authority
CY
Cyprus
Prior art keywords
ltb4
lefcotrien
stabilized
formulation
life
Prior art date
Application number
CY20101100940T
Other languages
English (en)
Inventor
Pierre Borgeat
Original Assignee
Ltb4 Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ltb4 Sweden Ab filed Critical Ltb4 Sweden Ab
Publication of CY1110841T1 publication Critical patent/CY1110841T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με νέο φαρμακευτικό σκεύασμα που περιλαμβάνει παράγοντα LΤΒ4 σε αλκαλικό pH, αποτελεσματικό στη σταθεροποίηση του παράγοντα LΤΒ4 και παρέχει σκεύασμα με αυξημένη διάρκεια ζωής. Το σκεύασμα της παρούσας εφεύρεσης έχει αυξημένη διάρκεια ζωής κατά προτίμηση τουλάχιστον 24 μήνες.
CY20101100940T 2004-09-20 2010-10-20 Σταθεροποιημενος φαρμακευτικος παραγοντας λευκοτριενιου β4 (ltb4) CY1110841T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61096204P 2004-09-20 2004-09-20
US63500904P 2004-12-13 2004-12-13
US63548204P 2004-12-14 2004-12-14
EP05786891A EP1796730B1 (en) 2004-09-20 2005-09-20 Stabilized leukotriene b4 (ltb4) agent pharmaceutical

Publications (1)

Publication Number Publication Date
CY1110841T1 true CY1110841T1 (el) 2015-06-10

Family

ID=35902513

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100940T CY1110841T1 (el) 2004-09-20 2010-10-20 Σταθεροποιημενος φαρμακευτικος παραγοντας λευκοτριενιου β4 (ltb4)

Country Status (23)

Country Link
US (1) US8664271B2 (el)
EP (1) EP1796730B1 (el)
JP (1) JP4767256B2 (el)
KR (1) KR101109735B1 (el)
CN (1) CN101039698B (el)
AT (1) ATE474603T1 (el)
AU (1) AU2005286161B2 (el)
BR (1) BRPI0516957A (el)
CA (1) CA2581156C (el)
CY (1) CY1110841T1 (el)
DE (1) DE602005022462D1 (el)
DK (1) DK1796730T3 (el)
EA (1) EA012982B1 (el)
ES (1) ES2349410T3 (el)
HK (1) HK1103652A1 (el)
NO (1) NO20071977L (el)
NZ (1) NZ553982A (el)
PL (1) PL1796730T3 (el)
PT (1) PT1796730E (el)
SI (1) SI1796730T1 (el)
TW (1) TWI361078B (el)
UA (1) UA96257C2 (el)
WO (1) WO2006032977A2 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1840114A1 (en) * 2006-03-30 2007-10-03 LTB4 Sweden AB Crystalline Leukotriene B4
CN102435443B (zh) * 2011-09-08 2014-04-02 中国汽车技术研究中心 汽车催化器快速老化数据采集***
JP6483593B2 (ja) * 2015-03-06 2019-03-13 アークレイ株式会社 血液検査装置および血液検査方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0179959A1 (en) * 1982-04-20 1986-05-07 Merck Frosst Canada Inc. Conjugates of leukotrienes with proteins
US4568559A (en) * 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4876505A (en) * 1988-05-27 1989-10-24 Westinghouse Electric Corp. Apparatus and method for monitoring steam turbine shroud clearance
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
US20040132820A1 (en) 1996-02-15 2004-07-08 Jean Gosselin Agents with leukotriene B4-like antiviral (DNA) and anti-neoplastic activities
US5780055A (en) * 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US5909734A (en) * 1996-12-03 1999-06-08 Regents Of The University Of Michigan Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense
US7914800B2 (en) * 2001-07-05 2011-03-29 Ltb4 Sweden Ab LTB4 as vaccine adjuvant
US20030232858A1 (en) 2002-06-14 2003-12-18 Barker Ronnie C. Use of hydroxyeicosatetraenoic acid compounds to treat dry mouth

Also Published As

Publication number Publication date
HK1103652A1 (en) 2007-12-28
US20060063837A1 (en) 2006-03-23
TWI361078B (en) 2012-04-01
DE602005022462D1 (de) 2010-09-02
ES2349410T3 (es) 2011-01-03
CA2581156C (en) 2011-07-12
WO2006032977A2 (en) 2006-03-30
AU2005286161B2 (en) 2010-09-09
EP1796730B1 (en) 2010-07-21
PL1796730T3 (pl) 2010-12-31
JP4767256B2 (ja) 2011-09-07
WO2006032977A3 (en) 2006-07-13
CA2581156A1 (en) 2006-03-30
US8664271B2 (en) 2014-03-04
CN101039698A (zh) 2007-09-19
BRPI0516957A (pt) 2008-09-30
DK1796730T3 (da) 2010-11-01
KR101109735B1 (ko) 2012-02-17
SI1796730T1 (sl) 2010-12-31
EP1796730A2 (en) 2007-06-20
EA012982B1 (ru) 2010-02-26
NZ553982A (en) 2009-09-25
CN101039698B (zh) 2011-11-09
AU2005286161A1 (en) 2006-03-30
PT1796730E (pt) 2010-10-26
EA200700676A1 (ru) 2007-10-26
KR20070085277A (ko) 2007-08-27
UA96257C2 (uk) 2011-10-25
TW200626175A (en) 2006-08-01
NO20071977L (no) 2007-04-18
JP2008513431A (ja) 2008-05-01
ATE474603T1 (de) 2010-08-15

Similar Documents

Publication Publication Date Title
MEP49208A (en) Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
ATE471144T1 (de) Intranasale verabreichung von schnell wirkendem insulin
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
DK1526839T3 (da) Orale farmaceutiske former for flydende lægemidler med forbedret biotilgængelighed
IL175220A (en) 3,5-substituted estrone derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for inhibiting 17beta-hydroxysteroid dehydrogenase type i enzyme
DE60105448D1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
WO2002051424A8 (fr) Medicaments contre les defaillances articulaires
BR0211282A (pt) Formulação farmacêutica
EA200901365A1 (ru) Стабилизированная фармацевтическая композиция, содержащая прегабалин
WO2005065657A3 (en) Solid compositions of low-solubility drugs and poloxamers
NZ547587A (en) Pharmaceutical compositions and methods for insulin treatment
MY143561A (en) Pregabalin composition
AP2003002716A0 (en) Medicinal compositions containing propenone derivatives.
IL192611A0 (en) Biologically active composition comprising ethylcellulose
BR0208161A (pt) Forma farmacêutica sólida orodispersìvel
CY1110841T1 (el) Σταθεροποιημενος φαρμακευτικος παραγοντας λευκοτριενιου β4 (ltb4)
HN2002000235A (es) Formulaciones en combinacion de derivados de 1, 4 - benzotiepina - 1, 1 - dioxido con otras sustancias activas, y su utilización
ITMI20022394A1 (it) Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ATE409040T1 (de) Kombination enthaltend substanzen mit npy- rezeptor affinität und substanzen mit 5-ht6- rezeptor affinität
BRPI0504082A (pt) emulsões refrescantes medicinais
TW200621304A (en) Pharmaceutical composition
PT1200088E (pt) Composicao contendo paracetamol e drotaverina
PT1299114E (pt) Composicao farmaceutica de diclofenac com base em vitamina e, papina e hialuronidase
WO2006024638A3 (de) Perorale darreichungsformen zur erzielung eines retardierungseffektes nach der arzneimitteleinnahme mit einer mahlzeit